ARRY is presumably where it is in terms of market cap because they've yet to show late-stage success with any of their drugs. One also has to keep in mind the large amount of Deerfield debt that comes due in 2014 (and is payable in stock or cash). I do, however, like ARRY's extensive pipeline and their track record for partnering and that, combined with the market cap, is why I am long. The MEK data due later this year is the big key for ARRY right now.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.